Viruses, Vol. 15, Pages 2451: Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Conclusion: according to the current evidence, the use of MET should be encouraged in diabetic patients with CHC in order to reduce the risk of HCC; however, a well-designed randomized controlled trial is needed to establish the generalizability of the beneficial effects of MET in this particular subset of patients.
Source: Viruses - Category: Virology Authors: Marco Sacco Davide Giuseppe Ribaldone Giorgio Maria Saracco Tags: Review Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Italy Health | Liver | Liver Cancer | Liver Disease | Liver Transplant | Metformin | Study | Taiwan Health | Transplants | Urology & Nephrology | Virology